Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis

Breast Cancer Clinical Trial

Official title:

Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01377363
• Other study ID #: CONVERTHER/GEICAM 2009-03
• Status: Completed
• Start date: December 11, 2009
• Est. completion date: November 30, 2012

Study information

• Verified date: March 2023
• Source: Spanish Breast Cancer Research Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a Prospective Clinical Trial without drugs, to determine the HER2 status in the metastasis of patients with primary breast cancer HER2. 32 Sites have been taking part in this Clinical Trial.

Description:

Population definition: Women previously diagnosed with a primary breast carcinoma who present locally recurrent or metastatic lesions and who meet the selection criteria. The expected sample size is 175 patients.

Observation period: Each patient in the study will be observed from their inclusion in the study until 1 year after the inclusion of the last patient in the study. These visits will match with the scheduled follow-up visits made by the patient according to the usual clinical practice of the site.

Determination of sample size: The calculation of the sample size will be based on determining a number of patients that will achieve the main objective of the study.

The fulfillment of the secondary objectives of the study will be obtained from the size determined by the main objective.

Main objective of the study is to: Prospectively determine the probability of conversion of the HER2 stage between the different subtypes of primary breast cancer (luminal, triple negative and HER2) and their respective metastases.

A review of the literature has allowed to find several published works with varying percentages of HER2 disagreements determined by IHQ + FISH or FISH, which have allowed to estimate an average percentage of disagreements of 10.45% (range between 4% and 20%). Considering the hypothesis that the level of disagreement in each of the different subtypes of primary, luminal, triple negative and HER2 breast cancer, is presented in an approximately similar frequency, that is to say approximately 10.45%.

From the aforementioned data, an average conversion rate to be expected of 10% will be assumed. An alpha risk of 0.05 will be accepted, with an accuracy of +/- 0.09 percentage units, with a bilateral contrast, for which it would be necessary to include 43 patients for each of the three groups mentioned above (luminal, triple negative and HER2), which consequently includes 129 patients. If a loss rate is assumed (patients registered with biopsies finally not performed or not valid, or with inconclusive results or reflecting other diagnoses) of approximately 25%, the necessary size would increase to a total of 172 patients.

Based on these calculations, the final sample size would be 175 patients

Recruitment information / eligibility

• Status: Completed
• Enrollment: 236
• Est. completion date: November 30, 2012
• Est. primary completion date: November 30, 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients who have given their written informed consent to participate in the study.

• Women over 18 years.

• Breast cancer locally recurrent or metastatic at first relapse or after successive progressions.

• Patient has to have available a sample of the primary tumor in paraffin.

• Patients who are planning for the next 6 weeks, the biopsy (fine needle aspiration / drainage of fluid cavities, open biopsy, core biopsy) of locally recurrent or metastatic lesion [local relapse in the chest wall, nodal , cutaneous or subcutaneous metastases, peripheral lymph nodes and other soft tissues accessible, bone metastases, visceral metastases (lung, liver, brain, etc..) or pleural effusion / ascites / pericardial / cerebrospinal] according to clinical practice center.

Exclusion Criteria:

• Patients with cognitive impairment that might impede a proper understanding of the written informed consent, according to medical criteria.

• Ipsilateral breast local relapses or contralateral breast away.

• Patients diagnosed with a second neoplasm, with the exception of cervical carcinoma in situ and non-melanoma skin carcinoma treated properly.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Locations

Country	Name	City	State
Spain	Complejo Hospitalario Universitario de A Coruña	A Coruña	La Coruña
Spain	Fundación Hospital Alcorcón	Alcorcón	Madrid
Spain	Hospital Virgen de los Lirios	Alcoy	Alicante
Spain	Hospital Punta de Europa	Algeciras	Cádiz
Spain	Hospital Clinic i Provincial de Barcelona	Barcelona
Spain	Hospital del Mar	Barcelona
Spain	Hospital San Pedro de Alcantara	Cáceres
Spain	Consorcio Hospitalario Provincial de Castellón	Castello de la Plana	Castellón
Spain	Hospital General de Elda	Elda	Alicante
Spain	Hospital Universitari de Girona Doctor Josep Trueta	Gerona
Spain	Hospital Universitario San Cecilio	Granada
Spain	Hospital Universitario Virgen de las Nieves	Granada
Spain	Hospital Universitario de Guadalajara	Guadalajara
Spain	Hospital Jerez de la Frontera	Jerez De La Frontera	Cádiz
Spain	Hospital Materno Insular de Canarias	Las Palmas De Gran Canaria	Las Palmas
Spain	Hospital Universitario Severo Ochoa	Leganés	Madrid
Spain	Hospital Clínico San Carlos	Madrid
Spain	Hospital Universitario Ramón y Cajal	Madrid
Spain	Althaia Xarxa Asistencial de Manresa	Manresa	Barcelona
Spain	Hospital General Universitario Morales Meseguer	Murcia
Spain	Hospital de Son Llàtzer	Palma De Mallorca	Islas Baleares
Spain	Hospital Universitario Quirón salud Madrid	Pozuelo De Alarcón	Madrid
Spain	Hospital de Sagunto	Sagunto	Valencia
Spain	Hospital Universitario Nuestra Señora de Candelaria	Santa Cruz De Tenerife	Tenerife
Spain	Hospital Universitario Virgen Macarena	Sevilla
Spain	Hospital Virgen de la Salud	Toledo
Spain	Hospital Arnau Vilanova	Valencia
Spain	Hospital Clínico Universitario de Valencia	Valencia
Spain	Hospital Universitari i Politècnic La Fe	Valencia
Spain	Hospital Universitario Doctor Peset	Valencia
Spain	Instituto Valenciano de Oncología	Valencia
Spain	Hospital Universitario Miguel Servet	Zaragoza

Sponsors (2)

Lead Sponsor	Collaborator
Spanish Breast Cancer Research Group	Roche Farma, S.A

Country where clinical trial is conducted

Spain, 

References & Publications (5)

Cejalvo JM, Martinez de Duenas E, Galvan P, Garcia-Recio S, Burgues Gasion O, Pare L, Antolin S, Martinello R, Blancas I, Adamo B, Guerrero-Zotano A, Munoz M, Nuciforo P, Vidal M, Perez RM, Chacon Lopez-Muniz JI, Caballero R, Peg V, Carrasco E, Rojo F, Pe — View Citation

de Duenas EM, Hernandez AL, Zotano AG, Carrion RM, Lopez-Muniz JI, Novoa SA, Rodriguez AL, Fidalgo JA, Lozano JF, Gasion OB, Carrascal EC, Capilla AH, Lopez-Barajas IB, Mateu MM, de Ceballos Reyna MH, Ferrando AO, Janez NM, Ballerini VC, Torres AA, Catala — View Citation

Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, Hollern DP, He X, Mott KR, Galvan P, Fan C, Selitsky SR, Coffey AR, Marron D, Braso-Maristany F, Burgues O, Albanell J, Rojo F, Lluch A, de Duenas EM, Rosen JM, Johnson GL, Carey LA, P — View Citation

Liu ZB, Ezzedine NE, Eterovic AK, Ensor JE, Huang HJ, Albanell J, Choi DS, Lluch A, Liu Y, Rojo F, Wong H, Martinez-Duenas E, Guerrero-Zotano A, Shao ZM, Darcourt JG, Mills GB, Dave B, Chang JC. Detection of breast cancer stem cell gene mutations in circu — View Citation

Lluch A, Gonzalez-Angulo AM, Casadevall D, Eterovic AK, Martinez de Duenas E, Zheng X, Guerrero-Zotano A, Liu S, Perez R, Chen K, Chacon JI, Mills GB, Antolin S, Blancas I, Lopez-Serra P, Carrasco E, Caballero R, Prat A, Rojo F, Gonzalez-Perez A, Meric-Be — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of degree of conversion of human epidermal growth factor receptor 2 (HER2) receptor between primary breast cancer and metastases	The conversion of HER2 is defined as the variation of the HER2 status between the primary tumor and the metastases, both from an initially negative to positive state and from an initially positive to negative state.; The definition of the different molecular subtypes of primary breast cancer will be the following: Luminal: immunohistochemical phenotype Estrogen Receptor (ER) positive and/or Progesterone Receptor (PR) positive, independently of HER2 status.; Triple negative: immunohistochemical phenotype ER negative, PR negative and HER2 negative.; HER2: immunohistochemical phenotype ER negative, PR negative and HER2 positive. For the calculation of this probability, a sample of the remnant of the primary tumor and the biopsy of the metastasis, performed according to the usual clinical practice of the site, will be sent to the central laboratory for analysis by immunohistochemistry (IHQ) and in situ hybridization (FISH) analysis.	2 years since the beginning of the Study
Secondary	To determine the probability of changes in ER and PR between different subtypes of primary breast cancer and their metastases	To obtain the contingency table to calculate the probability of changes in ER and PR between different subtypes of primary breast cancers and their metastases.	2 years since beginning of the Study
Secondary	Analyze the variability in the measurement of HER2, ER and PR between local laboratories and central laboratory	The contingency table will compare the measurement between the local laboratory in relation to the central laboratory, for each of the HER2 receptor ER and PR (for these two last ones of joint form)	2 years since the beginning of the Study
Secondary	Evaluate HER2 conversion rate compared to previously received treatment	For each of the types of treatment received will obtain the contingency table that allows to evaluate the conversion rate between the primary tumour HER2 and HER2 for metastases	2 years since the beginning of the Study
Secondary	Evaluate whether the location of biopsied metastases relates to the probability of conversion of HER2.	The frequency distribution of HER2 conversions according to biopsied metastases sites will be obtained to evaluate the possibility of finding statistically significant differences between them	2 years since the beginning of the Study
Secondary	Compare the disease-free survival (DFS) and survival post relapse (SPR) of patients with or without conversion of HER2 and ER/PR	Survival curves and disease-free survival post-relapse among patients with and without conversion of HER2 are compared using the log-rank test.In addition, for the analysis of post-relapse survival, also will be analyzed under stratified manner the patients with first metastases and subsequent progression.	2 years since the beginning of the Study
Secondary	Compare the response rate (RR) and time to progression (TTP) for subsequent anti-tumor treatment of patients with or without conversion of HER2	To compare statistically response rates and median time to progression (TTP) for patients with and without conversion of HER 2	2 years since the beginning of the Study
Secondary	Analyze the extent to which discrepancies in the HER2 receptor status, ER and PR between the primary tumor and metastases alter the clinical management of patients.	To obtain contingency tables between the variables HER2, ER and PR in relation to the change variable clinical management of patients and determine their statistical significance	2 years since the beginning of the Study
Secondary	Analyze the feasibility of performing biopsies.	To obtain the distribution of absolute and relative frequencies for the variable "viability of biopsies (analyzable / not studied)".	2 years since the beginning of the Study
Secondary	Evaluate if the HER2 status conversion is associated with activation of intracellular markers of the HER2 signaling pathway: phosphorylated MAPK (pMAPK), phosphorylated ERK (pERK), phosphorylated AKT (pAKT), PTEN, PIGF-1R in primary tumor and metastases	To obtain contingency tables for each of pMAPK, pERK, pAKT, pTEN, PIGF-1R proteins that relate their condition (+/-) in the primary tumor and metastases in HER2-discordant cases.	2 years since the beginning of the Study
Secondary	Check if there is any change in the molecular subtypes (luminal, triple negative, HER2) between primary tumors and metastases in patients with HER2 conversion	To obtain contingency tables to evaluate if there is any change of molecular phenotype between primary tumor and metastasis in patients with conversion HER2.Contingency tables will be obtained according to molecular subtype (luminal, triple negative, HER2) and based on molecular markers of the subtype.	2 years since the beginning of the Study

External Links

•   Spanish Breast Cancer Research Group (GEICAM) is a Spanish Breast Cancer Research Group